JP2016503817A - アンチグラニュリシン抗体及びその使用方法 - Google Patents

アンチグラニュリシン抗体及びその使用方法 Download PDF

Info

Publication number
JP2016503817A
JP2016503817A JP2015550860A JP2015550860A JP2016503817A JP 2016503817 A JP2016503817 A JP 2016503817A JP 2015550860 A JP2015550860 A JP 2015550860A JP 2015550860 A JP2015550860 A JP 2015550860A JP 2016503817 A JP2016503817 A JP 2016503817A
Authority
JP
Japan
Prior art keywords
seq
granulysin
antibody
antibodies
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015550860A
Other languages
English (en)
Japanese (ja)
Inventor
ライ，ジイェン−シュン
ワン，フン−リン
ファン，チャオ−ヤン
ロ，イン−ユン
チェン，ユエン−ツォン
チャン，ウォアン−ウォン
フー，チー−ヨン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DCB USA LLC
Original Assignee
DCB USA LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DCB USA LLC filed Critical DCB USA LLC
Publication of JP2016503817A publication Critical patent/JP2016503817A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2015550860A 2012-12-31 2013-12-31 アンチグラニュリシン抗体及びその使用方法 Pending JP2016503817A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261747800P 2012-12-31 2012-12-31
US61/747,800 2012-12-31
PCT/US2013/078441 WO2014106235A1 (en) 2012-12-31 2013-12-31 Anti-granulysin antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
JP2016503817A true JP2016503817A (ja) 2016-02-08

Family

ID=51017440

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015550860A Pending JP2016503817A (ja) 2012-12-31 2013-12-31 アンチグラニュリシン抗体及びその使用方法

Country Status (7)

Country Link
US (1) US9428575B2 (zh)
EP (1) EP2938632A4 (zh)
JP (1) JP2016503817A (zh)
CN (1) CN105026425A (zh)
AU (1) AU2013370009B2 (zh)
TW (1) TWI551609B (zh)
WO (1) WO2014106235A1 (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
KR20170056521A (ko) * 2014-09-16 2017-05-23 오바사이언스, 인크. 항-vasa 항체, 및 이것의 제조 및 사용 방법
US20180312922A1 (en) * 2015-10-30 2018-11-01 Chang Gung Memorial Hospital, Linkou Method and identification kit for identifying causative drug for drug hypersensitivity reaction
TWI606237B (zh) * 2015-10-30 2017-11-21 Chang Gung Memorial Hospital Linkou Methods and identification kits for the identification of sensitized drugs for drug allergy
BR112018013407A2 (pt) 2015-12-30 2018-12-18 Kodiak Sciences Inc anticorpos e conjugados dos mesmos
WO2018084836A1 (en) * 2016-11-02 2018-05-11 Development Center For Biotechnology Anti-tmcc3 immunoconjugates and uses thereof
WO2018136626A1 (en) 2017-01-18 2018-07-26 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
US11214613B2 (en) * 2017-05-30 2022-01-04 The University Of British Columbia Epitopes in the RNA recognition motif 1 (RRM1) of TDP-43 and misfolding-selective antibodies thereto
US20220226464A1 (en) 2019-05-28 2022-07-21 Massachusetts Institute Of Technology Methods and compositions for modulating immune responses
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder
AU2021248643A1 (en) * 2020-04-03 2022-10-27 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
CN115304670A (zh) * 2021-05-07 2022-11-08 华南农业大学 一种猫冠状病毒核衣壳蛋白的鼠源单克隆抗体及其编码基因和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003246748A (ja) * 2002-02-22 2003-09-02 Bml Inc 感染症治療剤
US20110014215A1 (en) * 2006-06-23 2011-01-20 Academia Sinica Granulysin and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI333978B (en) * 2006-06-23 2010-12-01 Academia Sinica Granulysin and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003246748A (ja) * 2002-02-22 2003-09-02 Bml Inc 感染症治療剤
US20110014215A1 (en) * 2006-06-23 2011-01-20 Academia Sinica Granulysin and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHIN.J.CELL MOL.IMMUNOL.,2010,26(6),P.563-5, JPN6016029940 *
EUR.J.IMMUNOL.,2004,34(8),P.2248-56, JPN6016029938 *

Also Published As

Publication number Publication date
AU2013370009A1 (en) 2015-07-23
US9428575B2 (en) 2016-08-30
EP2938632A4 (en) 2016-11-30
US20140186352A1 (en) 2014-07-03
WO2014106235A1 (en) 2014-07-03
TW201439116A (zh) 2014-10-16
AU2013370009B2 (en) 2016-11-17
TWI551609B (zh) 2016-10-01
EP2938632A1 (en) 2015-11-04
CN105026425A (zh) 2015-11-04

Similar Documents

Publication Publication Date Title
AU2013370009B2 (en) Anti-granulysin antibodies and methods of use thereof
TWI796328B (zh) Ｂ７-ｈ３抗體、其抗原結合片段及其醫藥用途
US20200347130A1 (en) CD96 Antibody, Antigen-Binding Fragment and Pharmaceutical use Thereof
US20220340654A1 (en) Antibody capable of binding to thymic stromal lymphopoietin and use thereof
US9315566B2 (en) Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
US20230138315A1 (en) Anti-angptl3 antibody and use thereof
CN110790839A (zh) 抗pd-1抗体、其抗原结合片段及医药用途
JP2018509894A (ja) Ｐｃｓｋ９抗体、及び医薬組成物とその使用
KR20190039937A (ko) 항-ApoC3 항체 및 이의 사용 방법
EP3981787A1 (en) Anti-connective tissue growth factor antibody and application thereof
AU2007320657B2 (en) Antibody recognizing C-domain of midkine
WO2021238854A1 (zh) 抗SARS-CoV-2刺突蛋白的单克隆抗体及其制备方法和用途
TWI840399B (zh) 結合人il-4r的抗體、其抗原結合片段及其醫藥用途
RU2819228C2 (ru) Антитело против фактора роста соединительной ткани и его применение
WO2022117079A1 (zh) 结合胸腺基质淋巴细胞生成素的抗体及其应用
KR20230145929A (ko) CD1a 항체 및 그의 용도
JP2023153754A (ja) ＣＤ１ａ抗体およびその使用
JP2023545075A (ja) ＣＤ１ａ抗体およびその使用
CN116082513A (zh) 分离的抗原结合蛋白及其用途
JP2021534229A (ja) 特定の腸内細菌の抗体媒介中和による免疫疾患の治療

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160808

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161101

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20170110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170303

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20170303

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170724

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180419